Provectus Biopharmaceuticals Files 8-K with Material Agreement

TL;DR

Provectus Bio (PVCT) filed an 8-K on 6/21, looks like a material agreement and charter amendments.

AI Summary

On June 21, 2024, Provectus Biopharmaceuticals, Inc. entered into a material definitive agreement. The company also amended its Articles of Incorporation and filed financial statements and exhibits as part of this 8-K filing.

Why It Matters

This filing indicates a significant development for Provectus Biopharmaceuticals, potentially involving new contracts, partnerships, or financial arrangements that could impact its future operations and stock value.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and amendments to articles of incorporation can alter corporate structure, requiring careful evaluation.

Key Players & Entities

• PROVECTUS BIOPHARMACEUTICALS, INC. (company) — Registrant
• June 21, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-36457 (identifier) — Commission File Number

FAQ

Key Financial Figures

• $0.001 — Convertible Preferred Stock, par value $0.001 per share (the "Series D Preferred Stoc

Filing Documents

• form8-k.htm (8-K) — 45KB
• ex3-1.htm (EX-3.1) — 11KB
• ex3-2.htm (EX-3.2) — 11KB
• ex10-1.htm (EX-10.1) — 29KB
• 0001493152-24-025080.txt ( ) — 273KB
• pvct-20240621.xsd (EX-101.SCH) — 3KB
• pvct-20240621_lab.xml (EX-101.LAB) — 33KB
• pvct-20240621_pre.xml (EX-101.PRE) — 22KB
• form8-k_htm.xml (XML) — 3KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2024 PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter) Delaware 001-36457 90-0031917 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 800 S. Gay Street , Suite 1610 , Knoxville , TN 37929 (Address of Principal Executive Offices) (Zip Code) (866) 594-5999 (Registrant's Telephone Number, Including Area Code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered None N/A N/A Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 1.01. Entry into a Material Definitive Agreement. On June 21, 2024, Provectus Biopharmaceuticals, Inc. (the "Company") entered into a Conversion Agreement (the "Conversion Agreement") with Dominic Rodrigues, the Company's Vice Chairman and President, that provides for the forfeiture and redemption of 11,416,262 shares (the "Forfeited Shares") of the Company's Series D Convertible Preferred Stock, par value $0.001 per share (the "Series D Preferred Stock"), held by Mr. Rodrigues in exchange for 1,141,626 shares of the Company's Series D-1 Convertible Preferred Stock, par value $0.001 per share (the "Series D-1 Preferred Stock"). The shares of Series D-1 Preferred Stock will be issued to Mr. Rodrigues after the filing of the Amendments (as defined below). Mr. Rodrigues agreed to enter into the Conversion Agreement in order to permit the Company to increase the number of authorized shares of Series D-1 Preferred Stock. The shares of the Company's Series D-1 Preferred Stock issued to Mr. Rodrigues as consideration for the Forfeited Shares are economically equivalent to the Forfeited Shares that he owned before entering into the Conversion Agreement. The foregoing description of the Conversion Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Conversion Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report and is incorporated herein by reference. Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On June 24, 2024, the Company filed a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D Convertible Preferred Stock (the "Series D Amendment") with the Secretary of State of the State of Delaware, reducing the number of authorized shares of Series D Preferred Stock from 12,374,000 to 957,100 shares. Following the filing of the Series D Amendment, the Company then filed on the same day a Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D-1 Convertible Preferred Stock (the "Series D-1 Amendment," and together with the Series D Amendment, the "Amendments") with the Secretary of State of the State of Delaware, increasing the number of authorized shares of Series D-1 Preferred Stock from 11,241,000 to 23,042,900 shares. The foregoing descriptions of the Series D Amendment and Series D-1 Amendment do not purport to be complete and are qualified in their entirety by reference to the full text of the Amendments, copies of which are filed as Exhibits 3.1 and 3.2, respectively, to this Current Report and are incorporated herein by reference. Item 9.01. Financial (d) Exhibits. Exhibit Number Description 3.1 Certificate of Amendment to the Certificate of Designation of Preferences, Rights, and Limitations of Series D Convertible Preferred Stock 3.2 Certificate of Amendment to the Certific

View Full Filing

View this 8-K filing on SEC EDGAR